PT2368882E - Pirimidinas anti-infecciosas e seus usos - Google Patents

Pirimidinas anti-infecciosas e seus usos Download PDF

Info

Publication number
PT2368882E
PT2368882E PT11171399T PT11171399T PT2368882E PT 2368882 E PT2368882 E PT 2368882E PT 11171399 T PT11171399 T PT 11171399T PT 11171399 T PT11171399 T PT 11171399T PT 2368882 E PT2368882 E PT 2368882E
Authority
PT
Portugal
Prior art keywords
crystalline forms
dihydropyrimidin
methanesulfonamide
naphthalen
dioxo
Prior art date
Application number
PT11171399T
Other languages
English (en)
Inventor
Dachun Liu
Yaya Liu
Rolf Wagner
Shuang Chen
Xiaochun Lou
Charles A Flentge
Douglas K Hutchinson
David A Betebenner
David A Degoey
Pamela L Donner
Warren M Kati
Allan C Krueger
Kenton L Longenecker
Clarence J Maring
Christopher E Motter
John K Pratt
John T Randolph
Todd W Rockway
Kent D Stewart
David M Barnes
Thaddeus S Ii Franczyk
Yi Gao
Anthony R Haight
John E Hengeveld
Brian J Kotecki
Geoff G Z Zhang
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PT2368882E publication Critical patent/PT2368882E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT11171399T 2007-09-17 2008-09-17 Pirimidinas anti-infecciosas e seus usos PT2368882E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97288107P 2007-09-17 2007-09-17
US9679208P 2008-09-13 2008-09-13

Publications (1)

Publication Number Publication Date
PT2368882E true PT2368882E (pt) 2014-11-27

Family

ID=40308557

Family Applications (3)

Application Number Title Priority Date Filing Date
PT121822779T PT2639226T (pt) 2007-09-17 2008-09-17 Pirimidinas anti-infeciosas e suas utilizações
PT11171399T PT2368882E (pt) 2007-09-17 2008-09-17 Pirimidinas anti-infecciosas e seus usos
PT08832330T PT2203431E (pt) 2007-09-17 2008-09-17 Pirimidinas anti-infecciosas e seus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT121822779T PT2639226T (pt) 2007-09-17 2008-09-17 Pirimidinas anti-infeciosas e suas utilizações

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT08832330T PT2203431E (pt) 2007-09-17 2008-09-17 Pirimidinas anti-infecciosas e seus usos

Country Status (22)

Country Link
US (3) US8188104B2 (pt)
EP (3) EP2203431B1 (pt)
JP (3) JP5734655B2 (pt)
CN (4) CN102746240B (pt)
AT (1) ATE519746T1 (pt)
CA (2) CA2699986C (pt)
CY (3) CY1115514T1 (pt)
DK (3) DK2639226T3 (pt)
ES (3) ES2368879T3 (pt)
HK (2) HK1148273A1 (pt)
HR (2) HRP20110809T1 (pt)
HU (1) HUS1500013I1 (pt)
LT (1) LTC2203431I2 (pt)
LU (1) LU92666I2 (pt)
MX (1) MX2010002902A (pt)
NL (1) NL300729I1 (pt)
NO (1) NO2015011I1 (pt)
PL (3) PL2368882T3 (pt)
PT (3) PT2639226T (pt)
RU (2) RU2539570C2 (pt)
SI (2) SI2203431T1 (pt)
WO (1) WO2009039134A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2639226T3 (en) 2007-09-17 2016-12-19 Abbvie Bahamas Ltd Anti-infective pyrimidines and uses thereof
AR070027A1 (es) * 2007-09-17 2010-03-10 Abbott Lab Agentes anti-infecciosos contra el virus hcv
PT2203430E (pt) 2007-09-17 2011-09-02 Abbott Lab N-fenildioxohidropirimidinas úteis como inibidores do vírus da hepatite c (vhc)
CA2730517A1 (en) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102164909A (zh) 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
CA2755023C (en) * 2009-03-25 2016-12-13 Abbott Laboratories Antiviral compounds and uses thereof
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
AU2010264802A1 (en) 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
EP2480533A1 (en) 2009-09-21 2012-08-01 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011061243A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EA201200863A1 (ru) * 2009-12-14 2013-01-30 Мерк Патент Гмбх Ингибиторы сфингозинкиназы
EP2513092A1 (en) * 2009-12-14 2012-10-24 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
CN103097027B (zh) 2010-07-16 2017-03-08 艾伯维巴哈马有限公司 用于催化反应的膦配体
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
EP3056486B1 (en) 2010-07-16 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing intermediates for antiviral compounds
SI2598482T1 (sl) 2010-07-29 2018-09-28 Oryzon Genomics, S.A. Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) * 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
MY187638A (en) 2011-10-20 2021-10-06 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107924A (pt) * 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
MX360161B (es) 2012-08-21 2018-10-09 Abbvie Inc Proceso para preparar compuestos antiviricos.
CN109260207A (zh) * 2012-10-18 2019-01-25 艾伯维公司 嘧啶二酮衍生物化合物的制剂
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
IL261744B (en) * 2016-03-17 2022-07-01 Fmc Corp A process for converting the s-enantiomer into a serial form
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017202207A1 (zh) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5162326A (en) * 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (pt) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
WO2001042225A2 (en) 1999-12-06 2001-06-14 F. Hoffmann-La Roche Ag 4-pyrimidinyl-n-acyl-l-phenylalanines
IL167955A (en) * 2000-02-04 2007-10-31 Sumitomo Chemical Co Inilines are converted by troiril
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2476279A1 (en) * 2002-02-14 2003-08-21 Lieven J. Stuyver Modified fluorinated nucleoside analogues
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
TW200505872A (en) * 2003-06-13 2005-02-16 Lg Life Science Ltd Hepatitis C virus inhibitors
BRPI0413234A (pt) * 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2008506702A (ja) * 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
EP1953147A1 (en) * 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
DK2639226T3 (en) 2007-09-17 2016-12-19 Abbvie Bahamas Ltd Anti-infective pyrimidines and uses thereof
AR070027A1 (es) * 2007-09-17 2010-03-10 Abbott Lab Agentes anti-infecciosos contra el virus hcv
PT2203430E (pt) 2007-09-17 2011-09-02 Abbott Lab N-fenildioxohidropirimidinas úteis como inibidores do vírus da hepatite c (vhc)
CA2730517A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
ATE519746T1 (de) 2011-08-15
ES2523864T3 (es) 2014-12-02
CY1115514T1 (el) 2016-04-13
CN102746240A (zh) 2012-10-24
CY2015013I2 (el) 2016-04-13
PL2203431T3 (pl) 2012-01-31
PL2368882T3 (pl) 2015-04-30
LU92666I2 (fr) 2015-11-24
US20090186912A1 (en) 2009-07-23
WO2009039134A1 (en) 2009-03-26
PT2203431E (pt) 2011-10-12
CN104628654A (zh) 2015-05-20
EP2203431A1 (en) 2010-07-07
DK2639226T3 (en) 2016-12-19
RU2010114827A (ru) 2011-10-27
SI2203431T1 (sl) 2011-12-30
US20120244119A1 (en) 2012-09-27
CN101842360B (zh) 2014-12-17
DK2368882T3 (en) 2014-12-01
NO2015011I2 (no) 2015-04-22
CY1115893T1 (el) 2017-01-25
EP2639226A1 (en) 2013-09-18
CN102746240B (zh) 2017-10-03
CN101842360A (zh) 2010-09-22
HUS1500013I1 (hu) 2016-11-28
CN104628655A (zh) 2015-05-20
HK1156033A1 (en) 2012-06-01
PT2639226T (pt) 2016-12-09
RU2539570C2 (ru) 2015-01-20
DK2203431T3 (da) 2011-11-21
JP5931683B2 (ja) 2016-06-08
NL300729I2 (pt) 2016-01-07
RU2014147354A (ru) 2015-07-10
PL2639226T3 (pl) 2017-02-28
CA2849420A1 (en) 2009-03-26
RU2014147354A3 (pt) 2018-07-30
JP2010539187A (ja) 2010-12-16
CA2849420C (en) 2016-07-12
US8501238B2 (en) 2013-08-06
NO2015011I1 (no) 2015-05-04
LTC2203431I2 (lt) 2017-01-25
MX2010002902A (es) 2010-06-02
EP2368882A1 (en) 2011-09-28
CA2699986A1 (en) 2009-03-26
US9139536B2 (en) 2015-09-22
EP2203431B1 (en) 2011-08-10
HRP20141102T1 (en) 2015-03-13
ES2368879T3 (es) 2011-11-23
US20140294766A1 (en) 2014-10-02
JP2015187106A (ja) 2015-10-29
JP5734655B2 (ja) 2015-06-17
NL300729I1 (pt) 2016-01-07
EP2639226B1 (en) 2016-08-31
HRP20110809T1 (hr) 2011-12-31
JP2013056886A (ja) 2013-03-28
US8188104B2 (en) 2012-05-29
SI2368882T1 (sl) 2015-02-27
ES2592961T3 (es) 2016-12-02
HK1148273A1 (en) 2011-09-02
CA2699986C (en) 2014-06-17
CY2015013I1 (el) 2016-04-13
EP2368882B1 (en) 2014-08-13

Similar Documents

Publication Publication Date Title
HUS1500013I1 (hu) Antiinfektiv hatású pirimidinek és alkalmazásuk
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
IL193725A0 (en) Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
WO2008089105A3 (en) Antiviral nucleoside analogs
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
EP2332951A3 (en) 6-modified bicyclic nucleic acid analogs
JO2686B1 (en) Vehicles
TW200612892A (en) Novel compounds
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
EP1869056A4 (en) NOVEL SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-d¨PYRIMIDINE DERIVATIVES
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
WO2007052023A3 (en) Novel compounds
TW200731974A (en) Transdermal system for verenicline
TW200618801A (en) Pyrimidine derivatives
NZ705225A (en) Process for preparing antiviral compounds
WO2006128802A3 (en) 3-methanesulfonylquinolines as gaba-b enhancers
WO2009006267A3 (en) N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
WO2007069050A3 (en) Processes for the preparation of alfuzosin
WO2007138462A3 (en) Aqueous oral formulations of risperidone
WO2009091346A3 (en) Stable pharmaceutical formulation and preparation methods
UA95085C2 (ru) Применение варденафила для лечения урологических расстройств
WO2006019673A3 (en) Jiadifenin analogs and uses thereof